Item Type: | Review |
---|---|
Title: | Enhanced T cell receptor gene therapy for cancer |
Creators Name: | Kieback, E. and Uckert, W. |
Abstract: | Importance of the field: Adoptive therapy with T cell receptor- (TCR-) redirected T cells has shown efficacy in mouse tumor models and first responses in cancer patients. One prerequisite to elicit effective anti-tumor reactivity is the transfer of high-avidity T cells. Their generation, however, faces several technical difficulties. Target antigens are often expressed at low levels and their recognition requires the use of high-affine receptors. Yet, mainly low-affine TCRs have been isolated from tumor-infiltrating lymphocytes. Furthermore, upon transfer into a T cell the introduced receptor has to compete with the endogenous TCR. Areas covered in this review: This review discusses how the functional avidity of TCR-modified T cells can be enhanced by i) increasing the amount of introduced TCR heterodimers on the cell surface; and ii) generating receptors with high affinity. Risks of TCR gene therapy and possible safety mechanisms are discussed. What the reader will gain: The reader will gain an overview of the technical developments in TCR and T cell engineering. Take home message: Despite technical obstacles many advances have been made in the generation of high-avidity T cells expressing enhanced TCRs. Mouse studies and clinical trials will evaluate the effect of these improvements. |
Keywords: | Gene Therapy, Adoptive Immunotherapy, Neoplasms, T-Cell Antigen Receptors, T-Lymphocytes, Treatment Outcome, Animals, Mice |
Source: | Expert Opinion on Biological Therapy |
ISSN: | 1471-2598 |
Publisher: | Informa Healthcare |
Volume: | 10 |
Number: | 5 |
Page Range: | 749-762 |
Date: | May 2010 |
Official Publication: | https://doi.org/10.1517/14712591003689998 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page